List of Excipients in Branded Drug XIIDRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	XIIDRA	lifitegrast	0078-0911	HYDROCHLORIC ACID	2029-06-25
Novartis Pharmaceuticals Corporation	XIIDRA	lifitegrast	0078-0911	SODIUM CHLORIDE	2029-06-25
Novartis Pharmaceuticals Corporation	XIIDRA	lifitegrast	0078-0911	SODIUM HYDROXIDE	2029-06-25
Novartis Pharmaceuticals Corporation	XIIDRA	lifitegrast	0078-0911	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	2029-06-25
Novartis Pharmaceuticals Corporation	XIIDRA	lifitegrast	0078-0911	SODIUM THIOSULFATE	2029-06-25

Xiidra Excipient Strategy and Commercial Opportunities for Lifitegrast

Last updated: August 9, 2026

Xiidra, the brand name for lifitegrast ophthalmic solution 5%, uses a relatively simple preservative-free aqueous formulation. Its commercial differentiation depends less on novel excipients than on container-closure performance, sterility assurance, ocular tolerability, dose convenience, and manufacturing cost. The most credible excipient opportunities are optimized buffer systems, viscosity and residence-time improvements, preservative-free multidose delivery, and supplier-controlled ophthalmic-grade raw materials.

Xiidra was approved by the U.S. Food and Drug Administration in 2016 for the signs and symptoms of dry eye disease in adults. Novartis acquired the product through its purchase of Xiidra owner Shire ophthalmology assets and sold Xiidra to Bausch + Lomb in 2023 for approximately $1.75 billion. [1,2]

What excipients are used in Xiidra ophthalmic solution?

Xiidra contains lifitegrast at a concentration of 50 mg/mL, equivalent to a 5% ophthalmic solution. The formulation is supplied in single-use, preservative-free containers.

Component	Function in the formulation
Lifitegrast	Active pharmaceutical ingredient; lymphocyte function-associated antigen-1 antagonist
Sodium chloride	Tonicity adjustment
Sodium citrate	Buffer component and pH control
Citric acid	Buffer component and pH control
Sodium hydroxide	pH adjustment
Hydrochloric acid	pH adjustment
Water for Injection	Vehicle

The labeled formulation has a target pH range of approximately 7.0 to 8.0. The product is packaged as a 0.2 mL single-use container, normally supplied in cartons containing 60 individual containers. [1]

The label does not identify a conventional antimicrobial preservative such as benzalkonium chloride, chlorobutanol, or polyquaternium-1. The preservative-free format is commercially relevant because chronic dry eye patients may use topical products multiple times daily and may experience ocular-surface irritation from preservatives.

Why is Xiidra’s preservative-free excipient strategy commercially important?

The preservative-free design reduces one source of ocular-surface exposure, but it increases packaging, filling, sterility, and supply-chain costs. A single-use format requires:

• High-throughput blow-fill-seal or aseptic filling capacity.
• Reliable low-volume dose control.
• Container integrity over the full shelf life.
• Low extractables and leachables.
• Packaging that permits dispensing without excessive residual volume.
• Robust protection against microbial ingress after opening.

The commercial tradeoff is clear:

Attribute	Single-use preservative-free format	Preserved multidose format
Ocular-surface preservative exposure	Lower	Higher
Container cost	Higher	Lower per dose
Microbial protection after opening	Based primarily on single-use design	Based on preservative and container system
Manufacturing complexity	Higher	Moderate to high
Patient convenience	Lower if frequent vial opening is required	Higher
Differentiation potential	High through packaging and usability	High through valve and delivery-system design

For Xiidra, the excipient system itself is not the primary barrier to competition. The stronger commercial barriers are sterile ophthalmic manufacturing, preservative-free packaging, device performance, regulatory equivalence, and the patent and exclusivity position.

What excipient opportunities exist for Xiidra and lifitegrast products?

1. Preservative-free multidose delivery

A preservative-free multidose bottle would be the most commercially valuable reformulation opportunity if it can maintain sterility without antimicrobial preservatives. Relevant technologies include:

• One-way valve systems.
• Airless multidose pumps.
• Filtered dispensing systems.
• Bag-in-bottle containers.
• Metered-dose ophthalmic pumps.
• Tip designs that reduce backflow and contamination.

This approach could reduce packaging waste and improve patient convenience. It would also create a potential line-extension strategy for Bausch + Lomb or a 505(b)(2) applicant, depending on the final formulation and delivery system.

The main technical risks are microbial ingress, dose uniformity, residual volume, sorption of lifitegrast to device materials, and extractables from elastomers, coatings, adhesives, and polymeric components.

2. Viscosity modification

A modest viscosity increase could extend precorneal residence time and reduce drainage through the nasolacrimal system. Candidate excipients for development screening could include:

• Hydroxypropyl methylcellulose.
• Hydroxypropyl cellulose.
• Carboxymethylcellulose.
• Polyvinyl alcohol.
• Hyaluronic acid or sodium hyaluronate.
• Poloxamers.
• Carbomer systems.

A viscosity-enhanced lifitegrast product would need to preserve:

• Optical clarity or acceptable appearance.
• Drop formation and delivery force.
• Chemical stability.
• Osmolality and pH.
• Patient comfort.
• Compatibility with the container and dispensing tip.

The commercial value would come from reduced dosing frequency, improved retention, or improved comfort rather than from the excipient itself. Any such product would likely face a more complex regulatory pathway than a standard generic equivalent.

3. Improved solubilization and chemical stability

Lifitegrast is formulated as an aqueous ophthalmic solution at a high active concentration. Solubilization and stability work may support lower-cost manufacturing or alternative delivery systems.

Potential development levers include:

• Buffer concentration.
• Ionic strength.
• pH optimization.
• Cosolvent screening.
• Surfactant or wetting-agent selection.
• Complexation.
• Oxygen-control strategies.
• Reduced interfacial exposure during filling and storage.

Changes to pH or buffer strength can affect ocular comfort, chemical degradation, osmolality, and the free concentration of the active ingredient. A supplier that can provide a validated, ophthalmic-grade buffer concentrate or premix could create value through batch-to-batch consistency and reduced formulation-development time.

4. Improved patient comfort

Dry eye products compete on tolerability as well as pharmacology. Excipient programs can target:

• Lower stinging on instillation.
• Reduced transient blur.
• Reduced viscosity-related visual disturbance.
• More physiologic osmolality.
• Improved wetting of the ocular surface.
• Lower particulate burden.
• Reduced interaction with tear-film proteins.

Comfort improvements may support premium positioning, but they must be measured against the existing Xiidra profile and competing products such as Restasis and generic cyclosporine ophthalmic products.

5. Container-closure and dispensing improvements

The most defensible product-development opportunity may be a container system rather than a new excipient. Opportunities include:

• Lower-residual-volume unit-dose vials.
• Easier twist-off or snap-off designs.
• Larger grip surfaces for patients with arthritis.
• Metered-dose dispensing.
• Reduced package volume.
• Recyclable or lower-material packaging.
• Integrated labeling and dose-counting systems.

These changes can support a product-specific patent estate if the claims cover the container, dispensing method, formulation-device interaction, or use conditions.

What formulations could compete with Xiidra?

The main formulation strategies are summarized below.

Strategy	Commercial objective	Likely regulatory complexity	Key technical barrier
Same 5% aqueous solution in unit-dose container	Generic substitution	ANDA, subject to applicable requirements	Pharmaceutical equivalence and device performance
Preservative-free multidose solution	Convenience and packaging savings	Potentially ANDA or 505(b)(2), depending on differences	Sterility after repeated use
Viscosity-enhanced solution	Longer ocular residence	Likely 505(b)(2) or new clinical support	Comfort, blur, and drop delivery
Lower-frequency formulation	Improve adherence	505(b)(2) or new drug pathway	Exposure and clinical efficacy
Lipid or nano-enabled system	Improve retention or delivery	Higher development burden	Scale-up, stability, and ocular tolerability
Combination product	Add anti-inflammatory or tear-film benefit	Combination-product and clinical requirements	Compatibility and safety

A conventional generic lifitegrast solution has the clearest near-term commercial path. A differentiated formulation has greater margin potential but carries higher clinical, device, manufacturing, and patent risk.

How does Xiidra compare with Restasis and generic cyclosporine?

Xiidra and Restasis address inflammatory mechanisms associated with dry eye disease, but their active ingredients and formulation systems differ.

Product	Active ingredient	Original approval	Typical dosage form	Preservative positioning
Xiidra	Lifitegrast 5%	2016	Aqueous ophthalmic solution	Preservative-free single-use
Restasis	Cyclosporine 0.05%	2002	Ophthalmic emulsion	Original product supplied in single-use containers
Cequa	Cyclosporine 0.09%	2018	Nanomicellar ophthalmic solution	Preservative-free
Vevye	Cyclosporine 0.1%	2023	Ophthalmic solution	Preservative-free

Restasis established the prescription anti-inflammatory dry eye category. Xiidra entered with a different mechanism and a solution-based formulation. Cequa and Vevye demonstrate that formulation technology, including nanomicellar systems and higher cyclosporine concentration, can support branded differentiation in a mature ophthalmic market. [3-5]

For excipient suppliers, the competitive lesson is that delivery-system technology can create more commercial value than incremental changes to a simple buffer system.

What patents protect Xiidra and lifitegrast products?

Xiidra protection has historically involved several layers:

1. Composition and active-ingredient patents.
2. Ophthalmic formulation patents.
3. Methods of treating dry eye disease.
4. Manufacturing and purification claims.
5. Container-closure or dosage-form claims.
6. Regulatory exclusivity and Orange Book-listed patents.

The FDA Orange Book is the controlling source for currently listed patents and exclusivity associated with an approved small-molecule drug application. Patent status must be assessed against the specific NDA, patent listing, terminal disclaimers, patent-term adjustment, pediatric extensions, and any court or settlement developments. [6]

For lifitegrast, commercial diligence should separate:

IP category	Relevance to an excipient or generic program
Active-ingredient claims	May block use of the molecule until expiration
Composition claims	May cover concentration, pH, buffers, or excipient combinations
Method-of-use claims	May affect labeling and Paragraph IV strategy
Device claims	May affect unit-dose or multidose packaging
Process claims	May create manufacturing risk even when formulation claims expire
Trade secrets	May affect impurity control, scale-up, and release testing

A formulation patent that claims a specific lifitegrast concentration, pH range, buffer system, or preservative-free presentation can be more important to an excipient strategy than a broad compound patent. A supplier should screen proposed excipients against composition claims, not only against active-ingredient patent claims.

When does Xiidra lose exclusivity and face generic entry?

Xiidra’s original FDA approval in 2016 means regulatory exclusivity has expired. The commercial timing of generic entry is controlled primarily by patent status, Paragraph IV certifications, litigation, settlements, and the ability of an ANDA applicant to demonstrate pharmaceutical equivalence and bioequivalence or obtain a waiver where applicable.

For ophthalmic solutions, generic developers must address:

• Active ingredient identity and strength.
• Dosage form and route.
• Inactive ingredients.
• pH and osmolality.
• Appearance and particulate matter.
• Container-closure system.
• Sterility.
• Drop size and delivered volume.
• Device compatibility.
• In-use stability where relevant.

An ANDA applicant may use a formulation that differs in inactive ingredients if the difference is permitted under FDA requirements and does not affect safety, efficacy, or product performance. A substantial change in formulation, route, delivery system, or clinical claims can move the program toward a 505(b)(2) pathway.

What Paragraph IV risks exist for Xiidra?

A lifitegrast ANDA applicant could file a Paragraph IV certification against relevant Orange Book-listed patents. The principal litigation risks would involve:

• Whether a proposed formulation falls within composition claims.
• Whether the generic label induces infringement of method-of-use claims.
• Whether the applicant can omit protected indications through a section viii statement.
• Whether a device or container patent is listed and enforceable.
• Whether a patent is invalid for lack of written description, enablement, novelty, or obviousness.
• Whether a settlement delays or permits an authorized generic launch.

A Paragraph IV notice can trigger a 30-month stay of FDA approval under the Hatch-Waxman Act, subject to statutory exceptions and court developments. [7] The commercial outcome depends on the asserted patents, claim scope, litigation timing, and settlement terms.

What is the FDA regulatory status of Xiidra?

Xiidra is an FDA-approved prescription ophthalmic solution under NDA 208073. It is indicated for the treatment of signs and symptoms of dry eye disease in adults. The product is a small-molecule drug, so biosimilar legislation does not apply. Competitors would pursue an ANDA or, for materially differentiated products, a 505(b)(2) application.

Regulatory issue	Xiidra implication
FDA pathway	NDA product; generic applicants generally use ANDA
Biosimilar risk	None; lifitegrast is not a biologic
505(b)(2) opportunity	Relevant for new delivery systems, dosing regimens, or materially different formulations
Orange Book	Relevant for listed patents and regulatory exclusivity
REMS	No prominent REMS requirement identified in the prescribing information
Preservative status	Preservative-free presentation creates device and sterility requirements
Clinical differentiation	May be needed for altered dosing frequency or delivery technology

Which companies are positioned to challenge Xiidra?

The competitive field includes three groups:

Generic ophthalmic manufacturers

Companies with sterile ophthalmic ANDA capabilities are the most direct potential challengers. Their advantages include established aseptic manufacturing, existing ophthalmology portfolios, and lower-cost packaging procurement.

Branded dry eye companies

Bausch + Lomb has direct commercial ownership of Xiidra and a broad ophthalmic portfolio. AbbVie remains relevant through Restasis and other eye-care assets. EyePoint, Harrow, Alcon, Santen, and other ophthalmology companies may compete through branded formulations, delivery systems, or channel strategies.

Excipient and device suppliers

The highest-value partners are suppliers with capabilities in:

• Ophthalmic-grade buffers.
• Low-endotoxin polymers.
• Preservative-free multidose systems.
• Blow-fill-seal packaging.
• Extractables and leachables testing.
• Sterility and container-closure integrity.
• Viscosity-modifying excipients.
• Micellar or nano-enabled delivery systems.

For suppliers, the commercial opportunity is stronger when the material is tied to a validated formulation or proprietary container system. Commodity sodium chloride, citric acid, and sodium citrate face price competition and limited switching costs.

How strong is the Xiidra patent estate for excipient-based products?

The estate should be considered layered rather than uniformly strong. Broad compound protection, if expired or nearing expiry, does not eliminate formulation risk. Conversely, a narrow formulation patent may be vulnerable if the claimed excipient combination is predictable or already disclosed in ophthalmic prior art.

A practical strength assessment should score:

Factor	Strong position	Weak position
Claim breadth	Covers broad formulation parameters	Covers a narrow excipient combination
Enablement	Supported by stability and clinical data	Limited examples
Differentiation	Clear performance advantage	Routine buffer or tonicity change
Commercial relevance	Covers the marketed presentation	Covers an unused formulation
Design-around	Few practical alternatives	Multiple substitute excipients
Evidence	Clinical, stability, and device data	Mostly prophetic examples

A simple buffer substitution is unlikely to create a durable moat by itself. A validated preservative-free multidose system, lower-frequency formulation, or clinically demonstrated residence-time improvement has greater potential for defensible protection.

What commercial opportunities exist in Xiidra excipients and packaging?

The most attractive opportunities are ranked below.

Opportunity	Margin potential	Development burden	Strategic attractiveness
Commodity buffer and tonicity supply	Low	Low	Limited
Ophthalmic-grade excipient supply with regulatory documentation	Moderate	Moderate	Stable
Ready-to-use sterile formulation concentrate	Moderate to high	High	Attractive
Preservative-free multidose device	High	High	Very attractive
Viscosity-enhanced lifitegrast formulation	High	High	Attractive but clinically exposed
Novel retention-enhancing system	High	Very high	Long-term option
Low-waste unit-dose packaging	Moderate	Moderate	Practical
Contract sterile fill-finish	Moderate	High	Attractive where capacity is constrained

Bausch + Lomb’s ownership creates a potential licensing or co-development target for suppliers with differentiated delivery systems. The clearest deal structures would involve milestone payments for formulation feasibility, device qualification, clinical proof of concept, and regulatory acceptance, followed by royalties or supply commitments.

What manufacturing and intellectual-property barriers affect Xiidra competition?

Manufacturing barriers include:

• Consistent dissolution or dispersion of lifitegrast at 5%.
• Control of pH and osmolality.
• Low bioburden before sterilizing filtration or aseptic filling.
• Compatibility with unit-dose polymer containers.
• Control of particulate matter.
• Container-closure integrity.
• Low residual volume.
• Long-term chemical stability.
• Efficient filling of very small volumes.

The principal IP barrier is the interaction between formulation and delivery system. A generic company may avoid a composition claim but still face risk from a container patent, method-of-use claim, or manufacturing-process patent.

What generic launch scenarios are most plausible?

Scenario 1: Conventional unit-dose generic

This is the most direct route. The applicant matches the reference product’s concentration, dosage form, preservative status, and key quality attributes. Price competition would likely be substantial, but unit-dose packaging costs could limit discount depth.

Scenario 2: Authorized generic

The brand owner or commercial partner launches an authorized generic through a licensee. This can preserve channel access and capture lower-price demand while protecting branded Xiidra positioning.

Scenario 3: Differentiated 505(b)(2) product

A sponsor introduces a preservative-free multidose package, improved viscosity profile, or reduced-frequency regimen. The product could command a premium but would require more extensive regulatory and clinical support.

Scenario 4: Formulation-led branded competition

A competitor uses a different active ingredient or delivery technology, such as a cyclosporine solution or advanced tear-film formulation. This does not require direct lifitegrast substitution but can reduce Xiidra share in the anti-inflammatory dry eye market.

Key Takeaways

• Xiidra uses a preservative-free 5% lifitegrast aqueous solution with sodium chloride, citrate buffer components, pH adjusters, and Water for Injection.
• The formulation is simple; the commercial complexity lies in sterile unit-dose packaging, device performance, and chronic-use tolerability.
• The strongest excipient opportunities involve viscosity control, residence-time improvement, preservative-free multidose delivery, and validated ophthalmic-grade supply.
• Commodity buffer ingredients offer limited differentiation and low switching costs.
• A lifitegrast generic is an ANDA opportunity, while a materially different delivery system may require a 505(b)(2) application.
• Xiidra has no biosimilar risk because lifitegrast is a small molecule.
• Orange Book-listed patents, Paragraph IV activity, settlements, and current litigation must be reviewed against the live FDA record before launch or licensing decisions.
• The highest-value IP strategy combines formulation claims with container, dispensing, manufacturing, and method-of-use claims.
• Bausch + Lomb’s ownership creates a potential commercial counterparty for excipient, device, and line-extension partnerships.

FAQs

Can Xiidra be reformulated with benzalkonium chloride?

A preserved formulation may be technically feasible, but it would alter the marketed preservative-free profile and could affect tolerability, labeling, regulatory pathway, and patent analysis.

Is sodium hyaluronate a viable excipient for lifitegrast?

Sodium hyaluronate is a plausible residence-time and comfort-enhancing candidate, but its use would require evaluation of viscosity, drop delivery, stability, particulate formation, and ocular tolerability.

Would a lifitegrast multidose bottle require new clinical trials?

The requirement would depend on the degree of formulation and device change. A closely comparable generic may use an ANDA pathway, while a materially different multidose system or dosing regimen could require 505(b)(2) data.

Does Xiidra have biosimilar competition?

No. Lifitegrast is a chemically synthesized small molecule. Competition would arise through generic ANDAs, 505(b)(2) products, and alternative branded dry eye treatments.

What is the most valuable excipient-related patent opportunity for Xiidra?

A patent covering a clinically supported preservative-free multidose system or a formulation that extends ocular residence while preserving comfort has greater commercial value than a patent covering a routine buffer substitution.

References

1. U.S. Food and Drug Administration. (2016). Xiidra prescribing information: Lifitegrast ophthalmic solution, 5%.
2. Bausch + Lomb. (2023). Bausch + Lomb completes acquisition of Xiidra and other ophthalmology assets from Novartis.
3. U.S. Food and Drug Administration. (2002). Restasis prescribing information: Cyclosporine ophthalmic emulsion, 0.05%.
4. U.S. Food and Drug Administration. (2018). Cequa prescribing information: Cyclosporine ophthalmic solution, 0.09%.
5. U.S. Food and Drug Administration. (2023). Vevye prescribing information: Cyclosporine ophthalmic solution, 0.1%.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
7. U.S. Food and Drug Administration. (2017). Hatch-Waxman amendments: Questions and answers on patent certifications and 30-month stays.